Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-24, Stock:PFE, The news for the past five days is as follows:
2018-08-17: NEWS1: 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval.NEWS2: 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval.NEWS3: 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval.NEWS4: Retailer Breaks Out As This Dow Jones Stock Is A New Emerging Winner.NEWS5: 3 Tough-Luck Tumbles in Healthcare: Are They Buys?.NEWS6: 3 Tough-Luck Tumbles in Healthcare: Are They Buys?.NEWS7: Pfizer, at Highest Price in a Decade, May Fall 10%.NEWS8: 3 Tough-Luck Tumbles in Healthcare: Are They Buys?.NEWS9: Company News For Aug 17, 2018.NEWS10: Company News For Aug 17, 2018.NEWS11: Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic.NEWS12: Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic.NEWS13: Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead.NEWS14: Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies.NEWS15: Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies.NEWS16: Life-Saving EpiPen Device Still Out of Stock at Many Pharmacies.NEWS17: Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic.NEWS18: Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen.NEWS19: Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen.NEWS20: Company News For Aug 17, 2018.NEWS21: If I Had to Buy 1 Stock in August, It Would Be This One.NEWS22: If I Had to Buy 1 Stock in August, It Would Be This One.NEWS23: EpiPen shortage has parents struggling during back-to-school season.NEWS24: EpiPen shortage has parents struggling during back-to-school season.NEWS25: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS26: If I Had to Buy 1 Stock in August, It Would Be This One.NEWS27: Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS28: Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS29: Glaxo, J&J&apos;s Dual Drug HIV Regimen Succeeds in Phase III Study.NEWS30: New Drugs Approved In July.NEWS31: New Drugs Approved In July.
2018-08-20: NEWS1: Amgen’s Product Performance in Q2 2018.NEWS2: Roche's Lung Cancer Drug Alecensa Gets Approval in China.NEWS3: Roche's Lung Cancer Drug Alecensa Gets Approval in China.NEWS4: Drugmakers Extend Summer Rally as Markets Regain Footing.NEWS5: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS6: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS7: Array BioPharma’s Immuno-Oncology Collaborations: Trial Update.NEWS8: Mylan Cuts Its Fiscal 2018 Guidance, Citing US Market Challenges.NEWS9: Pfizer Invites Public to View and Listen to Webcast of August 27 Conference Call with Analysts and Investors to Review Tafamidis Data Presentation at ESC Congress 2018.NEWS10: 3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro.NEWS11: 3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro.NEWS12: Pfizer Reaches Analyst Target Price.NEWS13: Pfizer Reaches Analyst Target Price.NEWS14: Mylan Has a Strong Balance Sheet despite Weak Q2 Performance.NEWS15: 3 Things Alnylam&apos;s Management Wants Investors to Know About the Launch of Onpattro.NEWS16: Non-Opioid Pain Therapy Market Opportunity for Teva.NEWS17: Allergan’s US Specialized Therapeutics Segment in Q2 2018.
2018-08-21: NEWS1: Cramer: Drug stocks' rally doesn't mean a recession is on....NEWS2: Jim Cramer: This Is a Rotation, Not a Recession.NEWS3: Pfizer Reached Our Price Target, So We Could Pause Here Before Heading Higher.NEWS4: Glaxo Stock Up This Year So Far: Will the Rally Continue?.NEWS5: Glaxo Stock Up This Year So Far: Will the Rally Continue?.NEWS6: FDA extends certain EpiPen expiration dates to combat shortage.NEWS7: Medtronic Earnings, Revenue Beat in Q1.NEWS8: Analysts’ Estimates and Recommendations for Amgen in August.NEWS9: Recent Developments for Amgen since Q2 2018.NEWS10: Mylan Finds a Disconnect between Market View and Intrinsic Value.NEWS11: Pfizer Stock Just Hit a 10-Year High: Buy, Sell, or Hold?.NEWS12: Pfizer Stock Just Hit a 10-Year High: Buy, Sell, or Hold?.NEWS13: Pfizer Stock Just Hit a 10-Year High: Buy, Sell, or Hold?.
2018-08-22: NEWS1: Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown.NEWS2: Exact Sciences CEO talks new partnership with Pfizer.NEWS3: Why Exact Sciences, Pure Storage, and Zynga Jumped Today.NEWS4: Why Exact Sciences, Pure Storage, and Zynga Jumped Today.NEWS5: Pfizer, Astellas revise two cancer drug trial protocols to speed up results.NEWS6: Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO?.NEWS7: Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO?.NEWS8: EXAS Soars On Pfizer Deal, MYND Delighted, ADMP Faces FDA In Sep..NEWS9: EXAS Soars On Pfizer Deal, MYND Delighted, ADMP Faces FDA In Sep..NEWS10: Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer.NEWS11: Why Exact Sciences, Pure Storage, and Zynga Jumped Today.NEWS12: Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX.NEWS13: Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX.NEWS14: Exact Sciences, Pfizer enter 4-year, $174M co-marketing pact to promote Cologuard.NEWS15: Should Alnylam&apos;s and Ionis&apos; Investors Be Worried About This Recent IPO?.NEWS16: Stocks Open Lower, Turn Mixed As Oil Prices, Retail Stocks Rally.NEWS17: [$$] Exact Sciences Shares Jump 26%.NEWS18: Four stocks to watch in today's blitz.NEWS19: Exact Sciences: Why the Stock Price Is Soaring.NEWS20: Better Buy: GlaxoSmithKline PLC vs. Pfizer.NEWS21: Better Buy: GlaxoSmithKline PLC vs. Pfizer.NEWS22: USMV, ONLN: Big ETF Inflows.NEWS23: USMV, ONLN: Big ETF Inflows.NEWS24: Stocks - Target, La-Z-Boy, Urban Outfitters Soar in Pre-market; Lowe’s Slides.NEWS25: Better Buy: GlaxoSmithKline PLC vs. Pfizer.NEWS26: Why Exact Sciences Stock Is Blasting Higher Today.NEWS27: Why Exact Sciences Stock Is Blasting Higher Today.NEWS28: Exact Sciences surges after marketing deal with Pfizer for cancer test.NEWS29: Why Exact Sciences Stock Is Blasting Higher Today.NEWS30: Exact Sciences shares jump 11% premarket on news of Pfizer collaboration on Cologuard.NEWS31: Exact Sciences signs marketing deal with Pfizer for cancer test.NEWS32: Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®.NEWS33: Exact Sciences Corp. (EXAS) Is Up Sharply On Pfizer Deal.NEWS34: Exact Sciences Corp. (EXAS) Is Up Sharply On Pfizer Deal.NEWS35: Exact Sciences & Pfizer To Co-promote Cologuard.NEWS36: Exact Sciences & Pfizer To Co-promote Cologuard.
2018-08-23: NEWS1: Big Pharma's Big Run Isn't Done.NEWS2: Why Exact Sciences Corporation Stock Is Jumping Again Today.NEWS3: Why Exact Sciences Corporation Stock Is Jumping Again Today.NEWS4: Alecensa Could Boost Roche’s Revenue Growth in 2018 and Beyond.NEWS5: Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer.NEWS6: Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer.NEWS7: Pfizer Amends Xtandi Study Protocols to Speed Up Completion.NEWS8: Pfizer Amends Xtandi Study Protocols to Speed Up Completion.NEWS9: Why Exact Sciences Corporation Stock Is Jumping Again Today.NEWS10: Pfizer Amends Xtandi Study Protocols to Speed Up Completion.NEWS11: Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer.NEWS12: Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?.NEWS13: Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?.NEWS14: The Latest Recommendations for Incyte.NEWS15: Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?.NEWS16: Xtandi Trials: Pfizer and Astella Amend the Protocols.NEWS17: Pfizer's Next Blockbuster Drug Has Big Promise. We'll Find Out Monday How Much..NEWS18: FDA extends EpiPen expiration dates because of shortage.

Answer: Rise